You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. IMPLANTED MEMBRANES FOR CHARACTERIZATION AND MONITORING

    SBC: DAKOTA TECHNOLOGIES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Many localities across the Unites States rely upon groundwater as the source of drinking water. In our industrialized society, pollution threatens the groundwater supply and, therefore, poses a significant health risk to the population. This Phase I SBIR research proposal offers an innovative solution to current inadequacies in groundwater monitoring. With t ...

    SBIR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  2. Developing Multi-targeting Antiviral Agents Against Herpes Simplex 1

    SBC: Quercus Molecular Design, LLC            Topic: NIAID

    Viruses from the human herpesvirus family are estimated to infectof the adult population worldwide and are responsible for lifelong debilitating and congenital infectionsSome members of this family are associated with human cancers and age related cognitive declineHerpes simplex virusHSVhas infected more thanbillion people under the age ofof the populationHSVcauses significant disease during acute ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Robust Predictor of Breast Cancer Risk

    SBC: Morgan and Mendel Genomics, Inc.            Topic: 103

    Summary Approximatelymillion women in the United States are at high risk for developing breast cancerbased on inheritance of a germline mutation in a gene in the double strand breakDSBrepair and cyclin checkpoint pathwaysMany are unaware of their genetic predispositionsbecause their family history is uninformative or unknownGenetic testing is important for identifying mutations in these genesbut i ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Robust Predictor of Colon Cancer Risk

    SBC: Morgan and Mendel Genomics, Inc.            Topic: 102

    Summary At leastpeople in the United States are at high risk for Lynch syndromebased on inheritance of a genetic mutation in the mismatch repairMMRor double strand breakDSBrepair pathwayMore than half of them are unaware of their riskbecause their family history is uninformative or unknownGenetic testing is important for identifying mutations in this pathwaybut in a large number of cases no mutati ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Osteopontin targeted therapy for primary CNS lymphoma

    SBC: MODULATION THERAPEUTICS, INC.            Topic: 102

    Abstract Primary central nervous system lymphoma PCNSL is an aggressive brain tumor with a dire unmet therapeutic need It has an overall incidence of per person years and is regarded as an orphan disease with potential for fast track approval Our group made a discovery via gene expression analysis that osteopontin OPN is the most upregulated gene in PCNSL compared to its non CNS ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Development of an a MC1R selective companion diagnostic imaging probe

    SBC: MODULATION THERAPEUTICS, INC.            Topic: 102

    The melanocortinreceptorMC Ris over expressed on uveal and cutaneous melanoma cellsbut notin healthy normal tissuesWe have developed a proprietary ligandMTIthat binds to MC R inmelanoma cells with high affinity and specificityThrough our SBIR Phase I contractwedemonstrated that MC R targetedAc DOTA MTIlacks of overt toxicity at single doses thatproduce significant efficacy against uveal and cutane ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Development of PEGylated MTI for the treatment of relapsed Myeloma

    SBC: MODULATION THERAPEUTICS, INC.            Topic: 102

    ABSTRACT Modulation Therapeutics is developing a first in class cyclic peptide coined MTI for the treatment of multiple myeloma The company currently has a license for the parent molecule which has been awarded a patent covering the intellectual property for both composition of matter and use in cancer in the US and Europe Modulation Therapeutics is now poised to further advance this class ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Assembled Porous Silica Membranes for Biomolecule SPE

    SBC: ADVANCED MATERIALS TECHNOLOGY, INC.            Topic: 400

    Abstract Life sciences research and other critical bioanalytical applications would strongly benefit from faster and higher efficiency sample preparation processes Sample preparation before high resolution analytical methods such as HPLC or LC MS can require effort and cost nearly equivalent to the actual sample analysis and data reduction Often sample preparation for proteomic glycoproteom ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. A Combined High-Throughput Single-Cell Transcriptomic and Secretomic Assay for Neurodegenerative Disease Biomarker Discovery

    SBC: ISOPLEXIS CORPORATION            Topic: 105

    In this Phase I application IsoPlexis proposes to deliver a novel method for targeted profiling of both the transcriptome and secretome from an array ofsingle central and peripheral immune cellsSpecificallywe will deliver a single cellmRNA and secreted protein capture assay with proven sensitivity for detecting the most important predictive biomarkers for neurodegenerative diseasesThere is growing ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Single-cell Phosphoprotein Assay to Evaluate Brain Tumor Therapeutic Resistance

    SBC: ISOPLEXIS CORPORATION            Topic: 102

    Although signal transduction inhibitors occasionally offer clinical benefit for cancer patientssignal flux emanating from oncogenes is often distributed through multiple pathwayspotentially underlying the resistance which causes failure of most such inhibitorsMeasuring signal flux through multiple pathwaysin response to signal transduction inhibitorsmay help uncover network interactions that contr ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government